0001425450-26-000032
SEC filingOrthoPediatrics reported first quarter 2026 revenue of $59.4 million, up 13% year-over-year, with improved adjusted EBITDA of $2.2 million and narrowed net loss per share to $0.45, while raising full-year 2026 revenue guidance and reaffirming $25.0 million adjusted EBITDA and breakeven free cash flow targets.
OrthoPediatrics delivered strong first quarter 2026 results anchored by 13% year-over-year revenue growth to $59.4 million, driven by broad-based strength across Trauma & Deformity (+14%), Scoliosis (+13%), and international markets (+22%). Gross margin remained stable at 73%, reflecting disciplined pricing and cost control despite increased sales volume and personnel-related operating expense growth. Adjusted EBITDA turned positive at $2.2 million versus a $0.4 million loss in Q1 2025, signaling meaningful progress toward profitability — a result management attributed to improved operational execution, clinic expansion, new product launches (e.g., Response, VerteGlide, 7D), and scaling of the Orthopedic Practice Support Business (OPSB). Free cash flow usage declined 40% year-over-year to $5.0 million, supported by lower set deployment and improved working capital metrics, reinforcing the company’s path to breakeven free cash flow for full-year 2026. Management raised full-year revenue guidance to $263.0–$267.0 million (up from $262.0–$266.0 million) and reiterated its $25.0 million adjusted EBITDA target, citing a multi-year product super cycle expected to drive higher ASPs, margin expansion, and deeper hospital partnerships. The press release emphasized execution across geographies and product lines — particularly robust international performance and OPSB growth — as key drivers of momentum entering 2026.